BNTC vs. SLGL, MEIP, SYBX, TCRT, RNXT, NNVC, CPIX, GDTC, BFRG, and GLYC
Should you be buying Benitec Biopharma stock or one of its competitors? The main competitors of Benitec Biopharma include Sol-Gel Technologies (SLGL), MEI Pharma (MEIP), Synlogic (SYBX), Alaunos Therapeutics (TCRT), RenovoRx (RNXT), NanoViricides (NNVC), Cumberland Pharmaceuticals (CPIX), CytoMed Therapeutics (GDTC), Bullfrog AI (BFRG), and GlycoMimetics (GLYC). These companies are all part of the "pharmaceutical preparations" industry.
Benitec Biopharma (NASDAQ:BNTC) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations, valuation and community ranking.
Benitec Biopharma received 34 more outperform votes than Sol-Gel Technologies when rated by MarketBeat users. Likewise, 63.73% of users gave Benitec Biopharma an outperform vote while only 63.09% of users gave Sol-Gel Technologies an outperform vote.
52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 4.3% of Benitec Biopharma shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Benitec Biopharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -1,331.01%. Sol-Gel Technologies' return on equity of -61.52% beat Benitec Biopharma's return on equity.
Benitec Biopharma presently has a consensus target price of $16.00, suggesting a potential upside of 68.95%. Sol-Gel Technologies has a consensus target price of $8.00, suggesting a potential upside of 982.25%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Sol-Gel Technologies is more favorable than Benitec Biopharma.
In the previous week, Benitec Biopharma had 1 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 5 mentions for Benitec Biopharma and 4 mentions for Sol-Gel Technologies. Benitec Biopharma's average media sentiment score of 0.84 beat Sol-Gel Technologies' score of 0.72 indicating that Benitec Biopharma is being referred to more favorably in the media.
Benitec Biopharma has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.
Benitec Biopharma has higher earnings, but lower revenue than Sol-Gel Technologies.
Summary
Benitec Biopharma and Sol-Gel Technologies tied by winning 8 of the 16 factors compared between the two stocks.
Get Benitec Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BNTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Benitec Biopharma Competitors List
Related Companies and Tools
